Evidence map›Paper›PMID 31631325›Full record

ArticleBiotechnology and bioengineering2020

Characterization and mutagenesis of Chinese hamster ovary cells endogenous retroviruses to inactivate viral particle release.

Pierre-Olivier Duroy, Sandra Bosshard, Emanuel Schmid-Siegert, Samuel Neuenschwander, Ghislaine Arib, Philippe Lemercier, Jacqueline Masternak, Lucien Roesch, Flavien Buron, Pierre-Alain Girod and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering.International journal of molecular sciences · 2023
    Review
  6. Cell culture bioprocessing - the road taken and the path forward.Current opinion in chemical engineering · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Pierre-Olivier DuroyInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4045-5240
Sandra BosshardInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3859-5113
Emanuel Schmid-SiegertVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID 0000-0003-1339-5120
Samuel NeuenschwanderVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Ghislaine AribSelexis SA, Plan-les-Ouates, Switzerland.
Philippe LemercierSwiss-Prot Group, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland.
Jacqueline MasternakInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.
Lucien RoeschInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.
Flavien BuronInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.
Pierre-Alain GirodSelexis SA, Plan-les-Ouates, Switzerland.
Ioannis XenariosVital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID 0000-0002-3413-6841
Nicolas MermodInstitute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7741-3186
SIB Swiss Institute of Bioinformatics · CHUniversity of Lausanne · CHL.A.C. (Switzerland) · CHLonza (Switzerland) · CH

Funding

Selexis SASwiss Government Commission for Technology and Innovation 17196.1 PFLS-LSUniversité de Lausanne
6 · The paper itself

Abstract

The Chinese hamster ovary (CHO) cells used to produce biopharmaceutical proteins are known to contain type-C endogenous retrovirus (ERV) sequences in their genome and to release retroviral-like particles. Although evidence for their infectivity is missing, this has raised safety concerns. As the genomic origin of these particles remained unclear, we characterized type-C ERV elements at the genome, transcriptome, and viral particle RNA levels. We identified 173 type-C ERV sequences clustering into three functionally conserved groups. Transcripts from one type-C ERV group were full-length, with intact open reading frames, and cognate viral genome RNA was loaded into retroviral-like particles, suggesting that this ERV group may produce functional viruses. CRISPR-Cas9 genome editing was used to disrupt the gag gene of the expressed type-C ERV group. Comparison of CRISPR-derived mutations at the DNA and RNA level led to the identification of a single ERV as the main source of the release of RNA-loaded viral particles. Clones bearing a Gag loss-of-function mutation in this ERV showed a reduction of RNA-containing viral particle release down to detection limits, without compromising cell growth or therapeutic protein production. Overall, our study provides a strategy to mitigate potential viral particle contaminations resulting from ERVs during biopharmaceutical manufacturing.

Indexed as

Endogenous RetrovirusesRNA, ViralAnimalsCHO CellsCricetinaeCricetulusCRISPR-Cas SystemsDrug ContaminationGene EditingGenome, ViralLoss of Function MutationMutagenesis, Site-DirectedVirionRNA, Viraladventitious agentsChinese hamster ovary cellsendogenous retroviral elementsgenome editing

Identifiers

PMID31631325
PMCPMC7003738
OpenAlexW2982062202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.